Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN (Reuters) - Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.


from Reuters: Health News https://ift.tt/2ku08Zf

No comments:

Post a Comment

Teen struggling w/ weight + no support at home, where the hell do I even start?

So I’m a teenager and I’ve been overweight/obese basically my whole life. And it’s been messing with me pretty bad. For the record, I don’...